Email ID
Password
Scrip   
AstraZeneca's Iressa gets EU approval for subgroup of NSCLC patients
03 July 2009
Malini Guha

AstraZeneca's EGFR-targeted anticancer Iressa (gefitinib) has received approval in the EU from the European Commission for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in the EGFR (epidermal growth factor receptor).This...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36